Aids Weekly Plus
Healio reported on a study of diabetic patients with hepatitis C virus (HCV) infection who received treatment with pegylated interferon plus ribavirin therapy. The researchers conducted a population-based cohort study to determine whether antiviral therapy for HCV infection resulted in improved outcomes in diabetic patients.
The researchers reviewed records of 2,267,270 Taiwanese individuals with diabetes from a population-based cohort study and selected 1,411 patients who had received standard HCV treatment; 1,411 matched patients who had not received treatment; and 5,644 individuals who did not have HCV infection. The researchers recorded incidence of end-stage renal disease (ESRD), ischemic stroke, and acute coronary syndrome (ACS) among the three groups from 2003 to 2011.
ESRD incidence among the treated patients was 1.1 percent, ischemic stroke 3.1 percent, and ACS 4.1 percent. Incidence in the untreated group was 9.3 percent, 5.3 percent, and 6.6 percent, respectively; while among the uninfected individuals incidence was 3.3 percent, 6.1 percent, and 7.4 percent, respectively. Multivariate adjusted hazard ratios were much lower for the group treated with antiviral therapy than for the untreated.
The researchers concluded that risks of ESRD, ischemic stroke, and ACS were reduced in HCV patients who were treated with antiviral therapy compared to controls and that HCV may have a role in patients developing clinical complications of diabetes. They acknowledge that additional research is necessary to determine the role of HCV and its mechanisms in causing diabetic complications.
The full report, “Antiviral Treatment for Hepatitis C Virus Infection is Associated with Improved Renal and Cardiovascular Outcomes in Diabetic Patients,” was published online in the journal Hepatology (2013; doi: 10.1002/hep.26892).